<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EB38DD1F-E01A-4709-B86C-F7412F3726D6"><gtr:id>EB38DD1F-E01A-4709-B86C-F7412F3726D6</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Wellington House</gtr:line1><gtr:line2>133-155 Waterloo Road</gtr:line2><gtr:postCode>SE1 8UG</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D85109E-D123-46DF-866F-2638197285A6"><gtr:id>4D85109E-D123-46DF-866F-2638197285A6</gtr:id><gtr:name>EDEN Biodesign</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4F1D2F3A-756D-4BC2-9E81-091D0356FECB"><gtr:id>4F1D2F3A-756D-4BC2-9E81-091D0356FECB</gtr:id><gtr:name>TAP Biosystems</gtr:name><gtr:address><gtr:line1>York Way</gtr:line1><gtr:line2>Royston</gtr:line2><gtr:line3>Herts</gtr:line3><gtr:postCode>SG8 5WY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/224536CE-14A2-4859-A63B-128877C872FE"><gtr:id>224536CE-14A2-4859-A63B-128877C872FE</gtr:id><gtr:name>HealthTech and Medicines Knowledge Transfer Network (Health KTN)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CC7FDF4-8B09-4C9F-8291-B964EA78CF79"><gtr:id>2CC7FDF4-8B09-4C9F-8291-B964EA78CF79</gtr:id><gtr:name>Lonza Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D31C478D-680E-46CA-8A7F-8CD1698914FE"><gtr:id>D31C478D-680E-46CA-8A7F-8CD1698914FE</gtr:id><gtr:name>BioIndustry Association</gtr:name><gtr:address><gtr:line1>7th Floor Southside</gtr:line1><gtr:line2>105 Victoria Street</gtr:line2><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2149BD49-CAB4-4F3F-AF53-29720F9C492F"><gtr:id>2149BD49-CAB4-4F3F-AF53-29720F9C492F</gtr:id><gtr:name>Polytherics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7D9D87A2-E892-4364-8ACE-DAF9FF7D0B52"><gtr:id>7D9D87A2-E892-4364-8ACE-DAF9FF7D0B52</gtr:id><gtr:name>BioPharm Services</gtr:name><gtr:address><gtr:line1>22 Wycombe End</gtr:line1><gtr:postCode>HP9 1NB</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECE55F4B-683C-4E67-B584-4B8536B9587D"><gtr:id>ECE55F4B-683C-4E67-B584-4B8536B9587D</gtr:id><gtr:name>PALL Europe</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CA73260-F337-418B-9AEA-3E5251F8B6BE"><gtr:id>1CA73260-F337-418B-9AEA-3E5251F8B6BE</gtr:id><gtr:name>Francis Biopharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EBF2F028-E935-4594-BEDE-45A732A2EAD0"><gtr:id>EBF2F028-E935-4594-BEDE-45A732A2EAD0</gtr:id><gtr:name>Association of the British Pharmaceutical Industry (ABPI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6C3712F6-BDFA-4D7B-9770-ABAEA9E72214"><gtr:id>6C3712F6-BDFA-4D7B-9770-ABAEA9E72214</gtr:id><gtr:name>Novozymes Biopharma UK Ltd</gtr:name><gtr:address><gtr:line1>Castle court</gtr:line1><gtr:line2>59 Castle Boulevard</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 1FD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC0F0C07-730C-4D2E-B236-54B9BAB45674"><gtr:id>FC0F0C07-730C-4D2E-B236-54B9BAB45674</gtr:id><gtr:name>Fujifilm</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/355663B8-CA62-4068-8A03-AF1CAED9C634"><gtr:id>355663B8-CA62-4068-8A03-AF1CAED9C634</gtr:id><gtr:name>Novo Nordisk UK Research Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/280F112E-1B3B-4C4E-9E42-EDEF4CF30536"><gtr:id>280F112E-1B3B-4C4E-9E42-EDEF4CF30536</gtr:id><gtr:name>Aegis Analytical</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70D9483D-0639-4D53-A44B-080D6B4237E1"><gtr:id>70D9483D-0639-4D53-A44B-080D6B4237E1</gtr:id><gtr:name>BTG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Biochemical Engineering</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D85109E-D123-46DF-866F-2638197285A6"><gtr:id>4D85109E-D123-46DF-866F-2638197285A6</gtr:id><gtr:name>EDEN Biodesign</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D31C478D-680E-46CA-8A7F-8CD1698914FE"><gtr:id>D31C478D-680E-46CA-8A7F-8CD1698914FE</gtr:id><gtr:name>BioIndustry Association</gtr:name><gtr:address><gtr:line1>7th Floor Southside</gtr:line1><gtr:line2>105 Victoria Street</gtr:line2><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7D9D87A2-E892-4364-8ACE-DAF9FF7D0B52"><gtr:id>7D9D87A2-E892-4364-8ACE-DAF9FF7D0B52</gtr:id><gtr:name>BioPharm Services</gtr:name><gtr:address><gtr:line1>22 Wycombe End</gtr:line1><gtr:postCode>HP9 1NB</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CA73260-F337-418B-9AEA-3E5251F8B6BE"><gtr:id>1CA73260-F337-418B-9AEA-3E5251F8B6BE</gtr:id><gtr:name>Francis Biopharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EBF2F028-E935-4594-BEDE-45A732A2EAD0"><gtr:id>EBF2F028-E935-4594-BEDE-45A732A2EAD0</gtr:id><gtr:name>Association of the British Pharmaceutical Industry (ABPI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB38DD1F-E01A-4709-B86C-F7412F3726D6"><gtr:id>EB38DD1F-E01A-4709-B86C-F7412F3726D6</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Wellington House</gtr:line1><gtr:line2>133-155 Waterloo Road</gtr:line2><gtr:postCode>SE1 8UG</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F1D2F3A-756D-4BC2-9E81-091D0356FECB"><gtr:id>4F1D2F3A-756D-4BC2-9E81-091D0356FECB</gtr:id><gtr:name>TAP Biosystems</gtr:name><gtr:address><gtr:line1>York Way</gtr:line1><gtr:line2>Royston</gtr:line2><gtr:line3>Herts</gtr:line3><gtr:postCode>SG8 5WY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/224536CE-14A2-4859-A63B-128877C872FE"><gtr:id>224536CE-14A2-4859-A63B-128877C872FE</gtr:id><gtr:name>HealthTech and Medicines Knowledge Transfer Network (Health KTN)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CC7FDF4-8B09-4C9F-8291-B964EA78CF79"><gtr:id>2CC7FDF4-8B09-4C9F-8291-B964EA78CF79</gtr:id><gtr:name>Lonza Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2149BD49-CAB4-4F3F-AF53-29720F9C492F"><gtr:id>2149BD49-CAB4-4F3F-AF53-29720F9C492F</gtr:id><gtr:name>Polytherics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECE55F4B-683C-4E67-B584-4B8536B9587D"><gtr:id>ECE55F4B-683C-4E67-B584-4B8536B9587D</gtr:id><gtr:name>PALL Europe</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6C3712F6-BDFA-4D7B-9770-ABAEA9E72214"><gtr:id>6C3712F6-BDFA-4D7B-9770-ABAEA9E72214</gtr:id><gtr:name>Novozymes Biopharma UK Ltd</gtr:name><gtr:address><gtr:line1>Castle court</gtr:line1><gtr:line2>59 Castle Boulevard</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 1FD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC0F0C07-730C-4D2E-B236-54B9BAB45674"><gtr:id>FC0F0C07-730C-4D2E-B236-54B9BAB45674</gtr:id><gtr:name>Fujifilm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/355663B8-CA62-4068-8A03-AF1CAED9C634"><gtr:id>355663B8-CA62-4068-8A03-AF1CAED9C634</gtr:id><gtr:name>Novo Nordisk UK Research Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/280F112E-1B3B-4C4E-9E42-EDEF4CF30536"><gtr:id>280F112E-1B3B-4C4E-9E42-EDEF4CF30536</gtr:id><gtr:name>Aegis Analytical</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70D9483D-0639-4D53-A44B-080D6B4237E1"><gtr:id>70D9483D-0639-4D53-A44B-080D6B4237E1</gtr:id><gtr:name>BTG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11C45689-C208-49DC-A95B-1B971827AEB3"><gtr:id>11C45689-C208-49DC-A95B-1B971827AEB3</gtr:id><gtr:name>Merck &amp; Co Inc</gtr:name><gtr:address><gtr:line1>Merck &amp; Co Inc</gtr:line1><gtr:line2>One Merck Drive</gtr:line2><gtr:line4>Whitehouse Station</gtr:line4><gtr:line5>NJ 08889-0100</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/777D702E-0F2D-41B5-A577-738C471240DC"><gtr:id>777D702E-0F2D-41B5-A577-738C471240DC</gtr:id><gtr:name>Aegis Analytical Corp</gtr:name><gtr:address><gtr:line1>1376 Miners Drive, Suite 106</gtr:line1><gtr:line4>Lafayette CO 80026</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/06931B49-20EF-4A5F-96AD-7DCAC53F4692"><gtr:id>06931B49-20EF-4A5F-96AD-7DCAC53F4692</gtr:id><gtr:name>NHS Improvement - QIPP</gtr:name><gtr:address><gtr:line1>Bryan House</gtr:line1><gtr:line2>61 Standishgate</gtr:line2><gtr:postCode>WN1 1AH</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55D98979-3BA2-42AE-AE3A-4887E8D111AE"><gtr:id>55D98979-3BA2-42AE-AE3A-4887E8D111AE</gtr:id><gtr:name>Avacta Group Plc</gtr:name><gtr:address><gtr:line1>Unit 651</gtr:line1><gtr:line2>Street 5</gtr:line2><gtr:line3>Thorp Arch Estate</gtr:line3><gtr:line4>Wetherby</gtr:line4><gtr:line5>Yorkshire</gtr:line5><gtr:postCode>LS23 7FZ</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47CE491B-8DF0-40F5-B5AE-ECCB94527E60"><gtr:id>47CE491B-8DF0-40F5-B5AE-ECCB94527E60</gtr:id><gtr:name>Eli Lilly S.A. - Irish Branch</gtr:name><gtr:address><gtr:line1>Dunderrow</gtr:line1><gtr:line2>Kinsale, Co</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F9085AC7-DC46-430A-943C-F189E5FF61B4"><gtr:id>F9085AC7-DC46-430A-943C-F189E5FF61B4</gtr:id><gtr:name>Syntaxin Ltd</gtr:name><gtr:address><gtr:line1>Units 4-10, The Quadrant</gtr:line1><gtr:line2>Barton Lane</gtr:line2><gtr:line4>Abingdon</gtr:line4><gtr:postCode>OX14 3YS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CE01BF9-4D85-4CB7-AAFF-90B2AE789E1A"><gtr:id>3CE01BF9-4D85-4CB7-AAFF-90B2AE789E1A</gtr:id><gtr:name>UCB Celltech</gtr:name><gtr:address><gtr:line1>208 Bath Road</gtr:line1><gtr:line4>Slough</gtr:line4><gtr:postCode>SL1 3WE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5DE06059-09E1-4A48-8CC6-A80FFDFBE118"><gtr:id>5DE06059-09E1-4A48-8CC6-A80FFDFBE118</gtr:id><gtr:name>Francis Biopharma Ltd</gtr:name><gtr:address><gtr:line1>38 Longmeadow</gtr:line1><gtr:line2>Riverhead</gtr:line2><gtr:postCode>TN13 2QY</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/45555183-99CB-4B93-BB81-CE9DDF06CF7E"><gtr:id>45555183-99CB-4B93-BB81-CE9DDF06CF7E</gtr:id><gtr:name>Lonza Biologics</gtr:name><gtr:address><gtr:line1>228 Bath Road</gtr:line1><gtr:line4>Slough</gtr:line4><gtr:postCode>SL1 4DX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF0020F8-9212-4670-ADC0-CBDFF5B93548"><gtr:id>DF0020F8-9212-4670-ADC0-CBDFF5B93548</gtr:id><gtr:name>GlaxoSmithKline</gtr:name><gtr:address><gtr:line1>Stockley Park West</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:postCode>UB11 1BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4DFF22E6-AE64-4655-B900-EECF9CBE6A18"><gtr:id>4DFF22E6-AE64-4655-B900-EECF9CBE6A18</gtr:id><gtr:name>The Association of the British Pharm Ind</gtr:name><gtr:address><gtr:line1>12 Whitehall</gtr:line1><gtr:postCode>SW1A 2DY</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/497AA87D-3C20-407B-BC41-F6F7A7E0099B"><gtr:id>497AA87D-3C20-407B-BC41-F6F7A7E0099B</gtr:id><gtr:name>The Office of Health Economics</gtr:name><gtr:address><gtr:line1>Southside</gtr:line1><gtr:line2>7th Floor</gtr:line2><gtr:line3>105 Victoria Street</gtr:line3><gtr:postCode>SW1E 6QT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D92716D0-081B-4976-A3CF-2E591C175698"><gtr:id>D92716D0-081B-4976-A3CF-2E591C175698</gtr:id><gtr:name>Novo Nordisk A/S</gtr:name><gtr:address><gtr:line1>Hagedornsvej 1</gtr:line1><gtr:postCode>2820</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F995CE27-4210-4CDC-863B-BD5EB94BC803"><gtr:id>F995CE27-4210-4CDC-863B-BD5EB94BC803</gtr:id><gtr:name>GE Healthcare</gtr:name><gtr:address><gtr:line1>Amersham Place</gtr:line1><gtr:postCode>HP7 9NA</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90A03C1B-6505-4F99-B847-E08735FD778F"><gtr:id>90A03C1B-6505-4F99-B847-E08735FD778F</gtr:id><gtr:name>MSD Biologics UK Ltd</gtr:name><gtr:address><gtr:line1>PO Box 2</gtr:line1><gtr:line2>Belasis Avenue</gtr:line2><gtr:postCode>TS23 1YN</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88051761-6C81-4292-ACAF-D3AD0C610862"><gtr:id>88051761-6C81-4292-ACAF-D3AD0C610862</gtr:id><gtr:name>MedImmune Ltd</gtr:name><gtr:address><gtr:line1>Milstein Building</gtr:line1><gtr:line2>Granta Park</gtr:line2><gtr:line3>Sir Aaron Klug Building</gtr:line3><gtr:postCode>CB21 6GH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68E35059-9942-4627-AAE5-C9BEFF11AA50"><gtr:id>68E35059-9942-4627-AAE5-C9BEFF11AA50</gtr:id><gtr:name>BTG International Ltd</gtr:name><gtr:address><gtr:line1>5 Fleet Place</gtr:line1><gtr:line2>Limeburner Lane</gtr:line2><gtr:postCode>EC4M 7RD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/941C2E74-C576-49DA-9987-CE40EF8A611D"><gtr:id>941C2E74-C576-49DA-9987-CE40EF8A611D</gtr:id><gtr:name>Pfizer</gtr:name><gtr:address><gtr:line1>235 East 42nd Street</gtr:line1><gtr:postCode>10017</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9409637-5F9E-459C-B0BC-0CE5B1890F34"><gtr:id>B9409637-5F9E-459C-B0BC-0CE5B1890F34</gtr:id><gtr:name>Technology Strategy Board</gtr:name><gtr:address><gtr:line1>North Star House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E718C6FE-9BEC-47F4-BA04-956E8F97389F"><gtr:id>E718C6FE-9BEC-47F4-BA04-956E8F97389F</gtr:id><gtr:firstName>Lazaros</gtr:firstName><gtr:surname>Papageorgiou</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EDE67D99-9688-44DB-AB92-25AE106B2D7C"><gtr:id>EDE67D99-9688-44DB-AB92-25AE106B2D7C</gtr:id><gtr:firstName>Suzanne</gtr:firstName><gtr:surname>Farid</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0EAB19CE-E446-4D6D-86A5-0959FD9A5ED3"><gtr:id>0EAB19CE-E446-4D6D-86A5-0959FD9A5ED3</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:surname>Titchener-Hooker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2E0BBB9D-2AE8-4368-A89A-665317171804"><gtr:id>2E0BBB9D-2AE8-4368-A89A-665317171804</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Dalby</gtr:surname><gtr:orcidId>0000-0002-0980-8167</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A32B7873-1625-498B-8A41-2207600C34AB"><gtr:id>A32B7873-1625-498B-8A41-2207600C34AB</gtr:id><gtr:firstName>Nina</gtr:firstName><gtr:otherNames>Frances</gtr:otherNames><gtr:surname>Thornhill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0773867B-E6D7-4977-9933-C44BEE027C00"><gtr:id>0773867B-E6D7-4977-9933-C44BEE027C00</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Brocchini</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1C0FE342-06DC-44B6-82A6-BDD87D6AD780"><gtr:id>1C0FE342-06DC-44B6-82A6-BDD87D6AD780</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Morris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FI033270%2F1"><gtr:id>ED9FA903-696E-4712-AAD9-31ECC0D38CDD</gtr:id><gtr:title>EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/I033270/1</gtr:grantReference><gtr:abstractText>In the 1980s it began to be possible to produce potentially unlimited quantities of human proteins by placing the gene defining them in a simple organism such as yeast. From this grew a new kind of medicine capable of treating conditions such as severe arthritis, haemophilia, growth deficiency, and some cancers that previously had no satisfactory treatments. As well as having great clinical value the resulting technology has become the basis of a new and fastest growing part of the pharmaceutical industry, described as biopharmaceuticals. Because the molecules involved are proteins, they are orders of magnitude larger and more complex than conventional drugs such as aspirin and their processing is much more demanding. They are also so complex that they cannot in general be characterised with precision except in relation to the methods by which they are made. That means the capacity to precisely define such processes is critical to clinical safety and commercial success. Full scale trials of the processes are so costly they can only be conducted once clinical promise is established but, given the number of factors governing processing of even first generation products, there have often been hold-ups so extensive as to delay availability to patients. UCL has pioneered micro scale methods that are sufficiently good at predicting efficient conditions for large scale performance that far fewer and better focussed large scale trials suffice. That resolves part of the problem but an even greater challenge is now emerging. The early biopharmaceuticals were in general the easiest ones to produce. The final scales were also relatively modest. Now, the next generation of biopharmaceuticals are more complex materials and with rising demand the scales are far larger so that processes push the boundaries of the possible. The combined complexity of the product and the process with so many variables to consider means that the managers need better systematic means of supporting their decisions. Already the cost of developing a single biopharmaceutical can exceed 0.7 billion and take 10 years. With more advanced biopharmaceuticals these figures tend to rise and yet the world's governments are facing a healthcare cost crisis with more older people. They therefore exert pressure on companies to reduce prices. Because the public wishes to have medicines that do not pose risks, regulations become ever more stringent so they are a major factor in defining the bioprocess. This also adds to the need for managers to have sector-specific decisional-support aids well grounded in the detailed engineering of the processes. Finally, it is now possible to apply molecular engineering to proteins and vaccines to enhance their therapeutic properties but this can also cause serious bioprocessing problems. The research vision developed with detailed input from UK industry experts will apply these methods as the foundation for another step change whereby much faster and lower cost information can be gathered and integrated with advanced decisional techniques to give managers a better foundation on which to base their policies. The academic team from leading UK universities provides the necessary continuum of skills needed to assess the ease of manufacture of novel drugs, the costs of processing and of delivery to patients. We will work with companies to test the outcomes to ensure they are well proven prior to use on new biopharmaceuticals. This will cut costs so that all the patients who might benefit can receive them and at the earliest possible date achieved within the severely restricted budgets now available to the NHS.</gtr:abstractText><gtr:potentialImpactText>WHO WILL BENEFIT FROM THE RESEARCH? The benefits of the proposed EPSRC Centre extend beyond the users who have already declared their interests and co-developed the proposal. This is a radical new opportunity for the industry which suffers from a diminished pipeline of blockbuster drugs. UK-based companies will benefit from access to a network and research activities within the extended EPSRC Centre. The Centre approach for more efficient and early evaluation of the potential value and manufacturability of new drugs treating diseases such as severe arthritis, currently untreatable cancers and multiple sclerosis offers the possibility of rapid and effective development for new clinical therapies and promises a new horizon for the sector. The research will also allow UK companies to better understand the likely development and manufacturing costs of their medicines and the associated administration costs, and their relationship to thresholds set by healthcare providers and agencies such as NICE. Potential patients will benefit because the EPSRC Centre innovations will significantly aid reduction in development times of macromolecular medicines, which is particularly crucial for those addressing previously unmet clinical needs and the treatment of severe conditions such as arthritis and cardiovascular disease, as well as vaccines for previously unpreventable viral infections and cancers. Benefits to the NHS relate to the possibility of constraining costs. The capacity to treat conditions such as rheumatoid arthritis much more effectively in ageing populations is vital but it still poses a problem with respect to stretched NHS budgets. A significantly greater number of drugs will be capable of meeting NICE's thresholds and thus benefit extended patient populations. The UK economy will benefit because academic research will complement the country's strength in bioscience discovery. Collaboration between bioprocess engineers, process modellers and protein biophysicists will ensure effective knowledge and skills transfer between the science and engineering base and UK industry. This will expand their position in the global healthcare market and attract further R&amp;amp;D investment from global business which recognises the UK as a good place to conduct these activities. Such retention of expertise, know-how and intellectual property will aid the capacity to remain internationally competitive. HOW WILL THEY BENEFIT FROM THE RESEARCH? Proteins are innately complex and labile so that bioprocess development times and hence costs tend to be high due to unforeseen issues that occur during scale-up of the manufacturing processes. The research will fundamentally address the ability to experimentally evaluate new protein therapy candidates on a rapid and low-volume platform, and use this data to create indices that flag up potential issues with sequences of manufacturing and formulation process steps. Advances in process modelling, optimisation and decision making tools will allow a more effective prediction of the bioprocess manufacturability, optimum downstream process, and fit to available manufacturing platforms and facilities, for new lead protein therapy candidates. This framework will provide significant cost-savings through a screen early - fail early approach. This minimises the risk of having to absorb the cost of late-failure of candidates during manufacturing scale-up or due to a need to re-optimise a bioprocess at a late stage in development. The research will also allow UK companies to gain a better prediction of the likely baseline costs of medicines and associated administration costs of a product, and their alignment to NICE thresholds, prior to product manufacturing development. These tools will enable the UK biotechnology industry to design more efficient bioprocesses and robust protein scaffolds that fit to available manufacturing platforms.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5840286</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fujifilm</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Fujifilm Diosynth Biotechnologies</gtr:department><gtr:description>Fujifilm Diosynth Biotechnologies</gtr:description><gtr:id>217B36CD-1918-445C-947E-6F4EBB724A60</gtr:id><gtr:outcomeId>b9d3264cb9d3266a-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. Fujifilm Diosynth Biotechnologies is an industry-leading biologics Contract Manufacturing Organization with locations in Research Triangle Park, North Carolina, USA, and Billingham, UK</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Eli Lilly</gtr:description><gtr:id>3D74D148-6B15-4E28-974B-2DD60AD030FA</gtr:id><gtr:outcomeId>b9d329d0b9d329e4-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. Lilly UK provides research and development, manufacturing and commercial operations.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MedImmune</gtr:description><gtr:id>13D700F2-63D7-44D6-BC64-2EAF5D39A5D8</gtr:id><gtr:outcomeId>b9d334b6b9d334ca-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. World's leading biotechnology companies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Merck &amp;amp; Co</gtr:description><gtr:id>5ED22C7A-2464-4064-ABC5-DF1C90C4C328</gtr:id><gtr:outcomeId>b9d32ec6b9d32eda-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation/Project Partne</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Avacta Group</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Avacta</gtr:description><gtr:id>00C445E5-6DF0-469F-A592-BFA5D358A2F3</gtr:id><gtr:outcomeId>b9d31a12b9d31a26-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation Partner. Avacta Group plc, a UK-based healthcare technology and consumables business, provides innovative and proprietary solutions to the life sciences/healthcare sector.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GE Healthcare</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GE Healthcare</gtr:description><gtr:id>33E73638-53D7-4697-9DF5-844526D33727</gtr:id><gtr:outcomeId>b9d33e7ab9d33e98-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HealthTech and Medicines Knowledge Transfer Network (Health KTN)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Health Tech and Medicines KTN</gtr:description><gtr:id>144B0E4A-DCF2-4668-B11C-E5D143E324CF</gtr:id><gtr:outcomeId>b9d313f0b9d31404-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Polytherics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Polytherics</gtr:description><gtr:id>01CA576A-F63E-4E15-9922-F20304AC21A8</gtr:id><gtr:outcomeId>b9d3163eb9d3165c-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. PolyTherics provides site-specific conjugation technologies and novel polymers to enable the development of better biopharmaceutical products.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BioIndustry Association</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The BioIndustry Association</gtr:description><gtr:id>8352EB2A-0235-4FE5-AE8D-FCD945829446</gtr:id><gtr:outcomeId>b9d30e0ab9d30e28-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation Partner. The BIA is at the forefront of UK bioscience, serving as its voice, connecting individuals and organisations, from SMEs, including innovative start-ups, to multi-national companies, helping to shape the future of the sector.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>EDEN Biodesign</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EDEN</gtr:description><gtr:id>E022BFEA-0D07-4DF8-B586-9C3812E65CCD</gtr:id><gtr:outcomeId>b9d31eb8b9d31ecc-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. Eden Biodesign is an integrated biopharmaceutical development organization and part of Watson Pharmaceuticals, Inc.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Francis Biopharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Francis BioPharm Consulting</gtr:description><gtr:id>C740A246-49D9-4E0A-92C7-6E6E3A313F06</gtr:id><gtr:outcomeId>b9d3037eb9d30392-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. The companies purpose is to supply expert advice to facilitate the development of biopharmaceutical products. Specific areas of expertise include Quality by Design, Process Development, Process Validation, Process Qualification, Characterisation and comparability of biopharmaceutical processes and products.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biopharm Services</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BioPharm Services</gtr:description><gtr:id>0C598C19-EE07-4619-AF25-EED3905890C4</gtr:id><gtr:outcomeId>b9d3239ab9d323b8-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. Biopharm Services is a bioprocess consultancy. The consultancy plus the BioSolve software help end users to make informed decisions quickly and so reduce time to market and business risk.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Association of the British Pharmaceutical Industry (ABPI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ABPI</gtr:description><gtr:id>BBCBDA10-6BEE-4125-937B-19E3F1A7F89F</gtr:id><gtr:outcomeId>b9d30b4eb9d30b6c-1</gtr:outcomeId><gtr:piContribution>Collobaring Organisation and Project Partner. The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novo Nordisk UK Research Foundation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novo Nordisk</gtr:description><gtr:id>3001A4C9-322F-466B-86F1-08908C4E8E80</gtr:id><gtr:outcomeId>b9d32b1ab9d32b38-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aegis Analytical</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Aegis Analytical</gtr:description><gtr:id>F3377EF2-004D-463A-BDFF-260799837C41</gtr:id><gtr:outcomeId>b9d314feb9d31512-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation Project Partner. Aegis Analytical Corp. provides Discoverant, an Enterprise Manufacturing Process Intelligence software platform that enables manufacturers to produce regulated and specialty products more efficiently.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BTG</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BTG PLc</gtr:description><gtr:id>2617025D-A4BE-4CE4-8631-28B3E6F35934</gtr:id><gtr:outcomeId>b9d31b16b9d31b2a-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. International specialist healthcare company. mission is to bring to market medical products that meet the needs of specialist healthcare physicians and their patients.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TAP Biosystems</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TAP Biosystems</gtr:description><gtr:id>F40D9CC3-8C5D-4B58-803B-9884BF9BFCCC</gtr:id><gtr:outcomeId>b9d32250b9d3226e-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. TAP Biosystems (formerly The Automation Partnership) provides innovative automation systems and consumables to improve productivity in life science research, development and production.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pfizer</gtr:description><gtr:id>14C0562F-2EB6-47C1-A7BD-30DF22F7C88C</gtr:id><gtr:outcomeId>b9d3310ab9d33128-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. Pfizer is a leading pharmaceutical company.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Health Protection Agency</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Health Protection Agency (HPA)</gtr:description><gtr:id>2877EDAA-2FEE-4E52-9DBB-5C1F76DC835C</gtr:id><gtr:outcomeId>b9d3275ab9d3276e-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. The Health Protection Agency is an independent UK organisation that was set up by the government in 2003 to protect the public from threats to their health from infectious diseases and environmental hazards. It does this by providing advice and information to the general public, to health professionals such as doctors and nurses, and to national and local government.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novozymes Biopharma UK ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novozymes Biopharma</gtr:description><gtr:id>E60D0A33-3BF7-45B3-8B76-B75B6ADD9764</gtr:id><gtr:outcomeId>b9d31da0b9d31dbe-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. Novozymes is a biotech company with a strong focus on enzyme production. We are committed to changing the very foundations of our industrial system for the better by using industrial biotechnology.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PALL Europe</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PALL Europe</gtr:description><gtr:id>15512FAF-B72E-47AE-A4DD-C262A54D9EC5</gtr:id><gtr:outcomeId>b9d31fbcb9d31fd0-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lonza Group</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Lonza Biologics</gtr:description><gtr:id>A854B91F-1E30-441E-955A-49AF899A02C5</gtr:id><gtr:outcomeId>b9d333a8b9d333c6-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner. Leading Supplier to the Life-Science Industries.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UCB Pharma</gtr:description><gtr:id>A38C7C6F-BC85-458E-86C9-ADF4304892DF</gtr:id><gtr:outcomeId>b9d33d76b9d33d94-1</gtr:outcomeId><gtr:piContribution>Collaborating Organisation and Project Partner</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ABB J?rgen Dormann Foundation for Engineering Education</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>856169AF-DD8D-4ECC-9647-92878ADEFC19</gtr:id><gtr:impact>Member of the board of the ABB J&amp;uuml;rgen Dormann Foundation for Engineering Education Member of the board of the ABB J&amp;uuml;rgen Dormann Foundation for Engineering Education, a Swiss charity that provides scholarships to engineering students in different parts of the world who can prove a high standard of academic achievement and who need financial support to be able to continue their studies.. Awarding Body - ABB J&amp;uuml;rgen Dormann Foundation, Name of Scheme - ABB J&amp;uuml;rgen Dormann Foundation for Engineering Education.</gtr:impact><gtr:outcomeId>584433e9e81f13.22745092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:url>http://new.abb.com/careers/opportunities/students/juergen-dormann-foundation</gtr:url><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ABB J?rgen Dormann Foundation for Engineering Education</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>CA1237C4-69DB-4CF4-8C9F-66E962707FCB</gtr:id><gtr:impact>Member of the board of the ABB J&amp;uuml;rgen Dormann Foundation for Engineering Education Member of the board of the ABB J&amp;uuml;rgen Dormann Foundation for Engineering Education, a Swiss charity that provides scholarships to engineering students in different parts of the world who can prove a high standard of academic achievement and who need financial support to be able to continue their studies.. Awarding Body - ABB J&amp;uuml;rgen Dormann Foundation, Name of Scheme - ABB J&amp;uuml;rgen Dormann Foundation for Engineering Education</gtr:impact><gtr:outcomeId>r-1735348349.19064162b8b47f8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research or patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IBLF Industrial Biotechnology Skills Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>B56B7A13-2688-4455-8586-72E88C01D672</gtr:id><gtr:impact>IBLF Industrial Biotechnology Skills Group, Leeds, 27 September 2012.. Awarding Body - IBLF Industrial Biotechnology Skills Group, Name of Scheme - IBLF Industrial Biotechnology Skills Group</gtr:impact><gtr:outcomeId>r-5447248709.8046092b8b4aaa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research or patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2408757</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre of Doctoral Trainining (CDT)</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K503332/1</gtr:fundingRef><gtr:id>0E9E2C9A-D971-4FD7-B1BA-866B18A0EBB0</gtr:id><gtr:outcomeId>5edc88ba5edc88ce</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240691</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC CDT equipment</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K005030/1</gtr:fundingRef><gtr:id>142F22A4-7BE1-4B8C-A25D-4A6A5A51C026</gtr:id><gtr:outcomeId>584172d029af69.98778822</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>43192</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC US Partnering</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K021354/1</gtr:fundingRef><gtr:id>64D10577-91AE-48C7-9390-2E22EDE99298</gtr:id><gtr:outcomeId>58417433d44457.27831678</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2410000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Centre for Doctoral Training 2012</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K503332/1</gtr:fundingRef><gtr:id>4BE773C0-1F21-4AB4-A7ED-0F57719FD59F</gtr:id><gtr:outcomeId>5841723392ed17.86013027</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>430000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC BRIC</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K011162/1</gtr:fundingRef><gtr:id>EDBDF8F0-3BE9-4BF3-9166-326B409345E1</gtr:id><gtr:outcomeId>584173c67f9b39.13857135</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>520000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Capital Equipment (Freeze-drying)</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/M028100/1</gtr:fundingRef><gtr:id>925E5CD0-7A82-439A-8788-5D671FAF83C8</gtr:id><gtr:outcomeId>584173548a8463.91550866</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MedImmune Cambridge</gtr:department><gtr:description>UCL-MedImmune Centre of Excellence</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>MedImmune</gtr:fundingOrg><gtr:id>3E566884-31DF-418F-8C70-4D5C454DEF77</gtr:id><gtr:outcomeId>5886ab7ae06881.21470446</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3710000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Centre for Doctoral Training</gtr:description><gtr:end>2022-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/L015218/1</gtr:fundingRef><gtr:id>F473F027-7034-4C72-8F4E-33A7DD200E06</gtr:id><gtr:outcomeId>584171b670b0a0.70398089</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2961745</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Formulation</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/N025105/1</gtr:fundingRef><gtr:id>6FF0A75D-B092-41C1-A313-8B4F0F61D687</gtr:id><gtr:outcomeId>58417128066153.01856976</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Future Manufacturing Hubs</gtr:description><gtr:end>2024-12-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/P006485/1</gtr:fundingRef><gtr:id>B45A9382-80C8-453F-91F0-71DED1FF1941</gtr:id><gtr:outcomeId>5899cc29650df0.44251116</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Demonstration projects have been used to export ideas into industry.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>A2B1B165-D570-4B12-B04B-15E311BCAF8C</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54623cdd223959.98705578</gtr:outcomeId><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have created methods by which industry cna decide upon appropriate candidates to take forward for manufacture and to ensure costs are such that the NHS can afford them.</gtr:description><gtr:exploitationPathways>Spinouts</gtr:exploitationPathways><gtr:id>82F4540C-21D8-4400-8ABD-0BA784AEFFC7</gtr:id><gtr:outcomeId>54623d3e94a186.54645537</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EPSRC SAN</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B4EE8172-03B9-4B25-94C9-CE36FCF4E612</gtr:id><gtr:impact>The EPSRC SAN is instrumental in helping the Council to formulate its research funding priorities</gtr:impact><gtr:outcomeId>587cb34bcf0ba1.71159353</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Elected Management Board Member of BBSRC BioProNet</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6C609E46-9630-4C97-A25C-B7B78C182ED9</gtr:id><gtr:impact>BioProNet coordinates the entire UK academic and industrial community for Bioprocess Manufacturing, via network meetings, workshops and managed proof of concept funding. Research outputs feed into larger InnovateUK proposals.</gtr:impact><gtr:outcomeId>5878dab2b48635.53807136</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EPSRC Balancing Capability</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FBA6ACF5-2FBA-4C29-80DE-DFD56FE84C73</gtr:id><gtr:outcomeId>58780790819ff8.61092876</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of a guideline committee - Elected Management Board Member of BBSRC BioProNet (2015)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>96AD1C75-4FA8-4CAD-98C0-AC14C1BED26E</gtr:id><gtr:impact>BioProNet is key to advising and shaping the funding opportunities between BBSRC and EPSRC</gtr:impact><gtr:outcomeId>587cb3d04ae1a7.70376390</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair of the Royal Society of Chemistry Biotechnology Interest Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FF7ACFD0-28F3-46DE-80C5-61A19E24E973</gtr:id><gtr:impact>The RSC BTG committee responds to the community of Chemists working in the area of biotechnology (in its broadest definition). The committee runs symposia, conferences and training events that fit the needs of its community.</gtr:impact><gtr:outcomeId>5878b23b6243a9.19910316</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Committee Member of the RSC Chemistry Biology Interface Division</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>49A1BAC3-E9DE-44DD-8283-0B964F04AB39</gtr:id><gtr:impact>The RSC CBID committee reviews Research Council strategy and opportunities in consultation with the UK Chemistry community.</gtr:impact><gtr:outcomeId>5878b36e6e7b46.00477587</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A suite of decisional tools were created to assist with decision-making related to cost-effective bioprocess design through to facility fit prediction.

Bioprocess lifecycle optimisation: A framework consisting of an evolutionary multiobjective optimization algorithm (EMOA) linked to a biomanufacturing process economics model has been created for designing more cost-ef?cient, robust and ?exible downstream processes for the manufacture of monoclonal antibodies (mAbs). The tool is tuned to discover sequences of chromatographic puri?cation steps and column sizing strategies that provide the best trade-off with respect to multiple objectives including cost of goods per gram (COG/g), robustness in COG/g, and impurity removal capabilities. Additional complexities accounted for by the framework include the topical decisions of whether to opt for batch or continuous processes and disposable or reusable equipment, as well as uncertainties and constraints. The framework is validated on industrially relevant case studies for therapeutic antibody manufacture varying in upstream and downstream processing train ratios, annual demands, and impurity loads. Results obtained by the framework are presented using a range of visualization tools, and indicate that uncertainty can cause otherwise optimal processes to become suboptimal. The optimal puri?cation processes discovered outperform the industrial standard with significant savings in COG/g. Guidelines are provided for choosing an optimal puri?cation process as a function of the objectives being optimized and impurity levels present. 

Facility fit prediction: Higher titre processes can pose facility ?t challenges in legacy biopharmaceutical puri?cation suites with capacities originally matched to lower titre processes. Bottlenecks caused by mismatches in equipment sizes, combined with process ?uctuations upon scale-up, can result in discarding expensive product. A data mining decisional tool was created for rapid prediction of facility ?t issues and debottlenecking of biomanufacturing facilities exposed to batch-to-batch variability and higher titres. The predictive tool comprised advanced multivariate analysis techniques to interrogate Monte Carlo stochastic simulation datasets that mimicked batch ?uctuations in cell culture titres, step yields and chromatography eluate volumes. A decision tree classi?cation method, CART (classi?cation and regression tree) was introduced to explore the impact of these process ?uctuations on product mass loss and reveal the root causes of bottlenecks. The resulting pictorial decision tree determined a series of if-then rules for the critical combinations of factors that lead to different mass loss levels. The tool facilitates the identification and investigation of different debottlenecking strategies and compares them in terms of mass output, direct cost of goods per gram and processing time, as well as consideration of extra capital investment and space requirements.</gtr:description><gtr:id>824124E8-5206-4B3A-B8E3-58562DBD6124</gtr:id><gtr:impact>The bioprocess optimisation tools provided an improved understanding of the relationship and trade-off between chromatography sequence selection, type of purification platform, equipment sizing and cost of goods. Case study outputs helped to identify strategies that provide significant reductions in cost of goods and the target performance that needs to be demonstrated experimentally for new technologies to compete. This in silico prediction of optimal strategies saves precious experimental resources. 

The facility fit prediction tools allow prediction of the root causes of facility fit challenges, which is critical to minimising the probability of having to discard expensive product. The framework developed compares different debottlenecking solutions for sub-optimised facilities in relation to their impact on mass output, COG and processing time, as well as consideration of extra capital investment and space requirements in order to support decision making. The frame work developed explores capability of multiproduct facilities to cater for low and high concentration formulations and enables to find optimal design for different product requirements.

The decisional tools research led to a number of peer-reviewed journal articles, demonstrator versions of the software with user-friendly interfaces for dissemination and knowledge transfer, user demonstration projects with companies (eg UCB, Syntaxin/Ipsen, Eden/Actavis, Repligen, Merck) with application of the tools to industry problems, new teaching materials integrated into the Masters level module Bioprocess Systems Engineering.

The mid-term review panel was positive about this major theme of research: &amp;quot;Flagship Project 2, which seeks to establish new decisional tools for biopharmaceutical life-cycle analysis, was judged to be of outstanding quality and promise by the panel, in part because it leverages all strengths and opportunities made possible by the networked Centre concept (e.g., user partnerships, ability to test and validate models across product classes and platforms), and because it clearly builds on the research programs for which the UCL Biochemical Engineering Department is most highly regarded&amp;quot;.

Sustainability: The CIM decisional tools outputs helped to underpin the creation of a UCL-MedImmune Centre of Excellence (2014-present, &amp;pound;0.8M) supporting six linked EngD projects so far, coordinated by a MedImmune-funded PDRA. Having established the CoE, the CIM PDRAs played a key role in knowledge transfer to the CoE researchers and provision of access to CIM toolkits. The linked projects have drawn upon CIM tools to create novel company-specific frameworks that enhance predictability early in the drug development cycle through integration of microscale experimentation, statistical correlations and cost modelling. Impact: The benefits of leveraging CIM outputs through the creation of a UCL-MedImmune CoE span sustainability, knowledge transfer, training, savings in cost and time and priority shifts in investment decisions.</gtr:impact><gtr:outcomeId>58869f420b7ce8.45455448</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Decisional Tools - Bioprocess Lifecycle Optimisation Tools and Facility Fit Tools</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A data analysis methodology was created to determine manufacturability indices to rank macromolecular products for their ease of manufacture. This methodology was applied to predict the ease of manufacture when generating high concentration formulations of therapeutic antibodies that reperesnt the next generation of biologics given the convenience of administration to the patients as subcutaneous injections at home rather than intravenous delivery in a hospital. These high concentration formulations present manufacturability challenges that especially hinder the final ultrafiltration.diafiltrations step of the process. Temproal multicritiera weighted score framework was developed to derive manufacturability indices based on viscosity and thermostability challenges. This enabled the optimal formulation to be selected for both efficacy and ease of manufacture.</gtr:description><gtr:id>2EB2026C-AE70-4447-9CD8-0633BDB3DB0F</gtr:id><gtr:impact>These indices act as early predictors of bioprocess performance - a concept completely novel to the sector. Ranking allows decision makers to weigh up manufacturability and product stability post formulation along with their knowledge of potential clinical efficacy, to select the most promising proteins from panels of candidates and most promising operating conditions, and eliminate those most likely to fail due to difficulties in bulk manufacture/ formulation. This work won a prize at the Recovery of Biological Products 16, Rostock, Germany, 27-31 July 2014 for its novelty and delivery.
This work has helped drive discussions to extend a UCL-MedImmune Centre of Excellence (2014-present, &amp;pound;0.8M) to apply such tools to live industrial projects. This will facilitate sustainability of the research beyond the CIM and knowledge transfer to industrial partners. The ability to predict manufacturability early on in the development cycle results in savings in cost and time and priority shifts in investment decisions:</gtr:impact><gtr:outcomeId>5886a58d44c9c5.25696313</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MAnufacturability indices framework</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6735CB1C-2E98-4AA5-9178-C5928A1D75A4</gtr:id><gtr:title>Optimal design and operation of distributed energy systems: Application to Greek residential sector</gtr:title><gtr:parentPublicationTitle>Renewable Energy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/008ef17b9b8206593a1ef4c5c24abefd"><gtr:id>008ef17b9b8206593a1ef4c5c24abefd</gtr:id><gtr:otherNames>Mehleri E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53d0080085f4702f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7FE830B-98EC-4C14-867F-A16095795314</gtr:id><gtr:title>Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a413f6f403354cf36ad118b7787c6608"><gtr:id>a413f6f403354cf36ad118b7787c6608</gtr:id><gtr:otherNames>Jenkins MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>5886a8b437eb00.65279519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92806B4A-BE57-48B4-AB44-966B31A3B3B2</gtr:id><gtr:title>The solution structure of rabbit IgG accounts for its interactions with the Fc receptor and complement C1q and its conformational stability.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/478fecd02f43a7355c5ce5d8c79e3940"><gtr:id>478fecd02f43a7355c5ce5d8c79e3940</gtr:id><gtr:otherNames>Rayner LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>doi_53cffcffc15c0f13</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DD46D23-746F-4EB5-AFAD-69A69BEEB2B7</gtr:id><gtr:title>Rapid prediction of facility fit and debottlenecking of antibody purification facilities</gtr:title><gtr:parentPublicationTitle>Pharmaceutical Discovery, Development and Manufacturing Forum 2014 - Core Programming Area at the 2014 AIChE Annual Meeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189e061b8ce0af7e94f7a4f7ed0c96d7"><gtr:id>189e061b8ce0af7e94f7a4f7ed0c96d7</gtr:id><gtr:otherNames>Yang Y.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5886a8b75a0eb3.62224688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EBF08B9-77CE-40C9-865E-858FD7C663B6</gtr:id><gtr:title>Host cell protein adsorption characteristics during protein A chromatography.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb848d7eb637dd0acb7a9882892725fe"><gtr:id>bb848d7eb637dd0acb7a9882892725fe</gtr:id><gtr:otherNames>Tarrant RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc25221b66</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A48FB59-4847-4194-8BD2-11CACE0E1245</gtr:id><gtr:title>Assessment of the manufacturability of Escherichia coli high cell density fermentations.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4ab249773ad8712a26dea6eef0b38a2"><gtr:id>c4ab249773ad8712a26dea6eef0b38a2</gtr:id><gtr:otherNames>Perez-Pardo MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc25b13075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EFBC9A0-CF8B-47AC-8C05-6BC8342EFED1</gtr:id><gtr:title>CHALLENGES OF LIFE CYCLE ASSESSMENT (LCA) IN THE BIOPHARMACEUTICAL INDUSTRY</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3073deb6d0e745eb74b74f17a70dafa"><gtr:id>a3073deb6d0e745eb74b74f17a70dafa</gtr:id><gtr:otherNames>S.V Ramasamy (Speaker)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_43796107111405debc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA8B5CE5-DF80-4A43-9E96-7E12EC9D7E32</gtr:id><gtr:title>The hybrid experimental simplex algorithm--an alternative method for 'sweet spot' identification in early bioprocess development: case studies in ion exchange chromatography.</gtr:title><gtr:parentPublicationTitle>Analytica chimica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fbe47e0e9d172812888efa2471b1486"><gtr:id>4fbe47e0e9d172812888efa2471b1486</gtr:id><gtr:otherNames>Konstantinidis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-2670</gtr:issn><gtr:outcomeId>doi_53cfe1fe17d42fbe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E89EB13C-4E01-49BB-A7FF-6DBF7717E070</gtr:id><gtr:title>Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80d42e5a9bf05772c1f0b5180c453dbf"><gtr:id>80d42e5a9bf05772c1f0b5180c453dbf</gtr:id><gtr:otherNames>Teo I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>doi_53cfc4fc4358d7aa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BDBE710-FC60-42D8-BA71-F2630B901952</gtr:id><gtr:title>Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/614499d6dfd60e0aac13fcc6156c92cd"><gtr:id>614499d6dfd60e0aac13fcc6156c92cd</gtr:id><gtr:otherNames>Yang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>5a2fec26752d54.02153701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>350F4A10-184B-4BC4-98CC-ED95F6911EDC</gtr:id><gtr:title>Biocatalysis for Green Chemistry and Chemical Process Development - Tao/Bioctalysis Green Chemistry</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30db0da598a7c069d24c3586fe4c08c9"><gtr:id>30db0da598a7c069d24c3586fe4c08c9</gtr:id><gtr:otherNames>Ho S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>9780470437780</gtr:isbn><gtr:outcomeId>doi_53cfbffbf0f092c5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2767AEE8-CA0C-4129-84B7-7B4EF8A1F63B</gtr:id><gtr:title>A novel efficient optimisation system for purification process synthesis</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9813f110add19d9c418fa19a30a48a37"><gtr:id>9813f110add19d9c418fa19a30a48a37</gtr:id><gtr:otherNames>Polykarpou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53cfe6fe620522b9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A16D55FF-0010-43F5-B4E5-F4E624D2DFE0</gtr:id><gtr:title>Economic analysis of Royalactin production under uncertainty: Evaluating the effect of parameter optimization.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a6cc20c32295443dddfa677916ea7a7"><gtr:id>5a6cc20c32295443dddfa677916ea7a7</gtr:id><gtr:otherNames>Torres-Acosta MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>56d5a1c9c9b2c1.47968160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D8AE11A-C883-464F-A917-2320B5137ECE</gtr:id><gtr:title>Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(a-Glutamic Acid) complex.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/743f63d512ba4a6cc48138715fbbdc85"><gtr:id>743f63d512ba4a6cc48138715fbbdc85</gtr:id><gtr:otherNames>Mohamed-Ahmed AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>doi_53d0700705e92106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67B6197B-4598-469E-8C8B-F06C30F0DCD9</gtr:id><gtr:title>Mass transfer coefficient determination in three biphasic systems (water-ionic liquid) using a modified Lewis cell</gtr:title><gtr:parentPublicationTitle>Chemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ed36b283020c26e6bf7231dee8ec4df"><gtr:id>2ed36b283020c26e6bf7231dee8ec4df</gtr:id><gtr:otherNames>Melgarejo-Torres R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53cfe8fe821b69d9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F89823FF-0232-429B-975A-580F29651AEF</gtr:id><gtr:title>Characterisation of ilomastat for prolonged ocular drug release.</gtr:title><gtr:parentPublicationTitle>AAPS PharmSciTech</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd84a5964e8adc4b64d8b2e8d5630cc7"><gtr:id>cd84a5964e8adc4b64d8b2e8d5630cc7</gtr:id><gtr:otherNames>Parkinson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1530-9932</gtr:issn><gtr:outcomeId>doi_53d07c07c4534050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7E30A5F-50DB-4418-B039-575E60B81407</gtr:id><gtr:title>Fair electricity transfer price and unit capacity selection for microgrids</gtr:title><gtr:parentPublicationTitle>Energy Economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/832216c3df80b3e815bce6a592c6f125"><gtr:id>832216c3df80b3e815bce6a592c6f125</gtr:id><gtr:otherNames>Zhang D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53cff0ff0305775e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6198BBF4-7CBA-4FFD-8B23-546B885A8294</gtr:id><gtr:title>Use of microwells to investigate the effect of quorum sensing on growth and antigen production in Bacillus anthracis Sterne 34F2.</gtr:title><gtr:parentPublicationTitle>Journal of applied microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a47dd00186b8c415246d773697cb9a93"><gtr:id>a47dd00186b8c415246d773697cb9a93</gtr:id><gtr:otherNames>Mukhopadhyay TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1364-5072</gtr:issn><gtr:outcomeId>doi_53d0640646f69705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3B97D5F-3E60-447C-9CB9-B0913437DB36</gtr:id><gtr:title>A decision-support tool for designing cost-effective biopharmaceutical manufacturing processes</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf5d9ef09b13dbe70a7107e67025a304"><gtr:id>bf5d9ef09b13dbe70a7107e67025a304</gtr:id><gtr:otherNames>Sofia Simaria (Speaker)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_51324302621406f838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC32A78D-B30C-4F09-8AB6-386A86520EDF</gtr:id><gtr:title>Tuning evolutionary multiobjective optimization for closed-loop estimation of chromatographic operating conditions</gtr:title><gtr:parentPublicationTitle>Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40327c7d26c2bddafaf8596200c75e1d"><gtr:id>40327c7d26c2bddafaf8596200c75e1d</gtr:id><gtr:otherNames>Allmendinger R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>16113349 03029743</gtr:issn><gtr:outcomeId>5886a8b25f26e5.98800617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54290FC3-2934-4D88-B766-48361DB85EC8</gtr:id><gtr:title>Assessment of quality of life after surgery for spinal metastases: position statement of the Global Spine Tumour Study Group.</gtr:title><gtr:parentPublicationTitle>World neurosurgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d29bc7d6528d50f36b7719a2395fbb26"><gtr:id>d29bc7d6528d50f36b7719a2395fbb26</gtr:id><gtr:otherNames>Choi D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1878-8750</gtr:issn><gtr:outcomeId>doi_53d00f00f618da55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE3E1992-07CE-4265-B52D-3C91DC209CB6</gtr:id><gtr:title>Ethnic variations in overweight and obesity among children over time: findings from analyses of the Health Surveys for England 1998-2009.</gtr:title><gtr:parentPublicationTitle>Pediatric obesity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e84b7b240a215a94b2e6183626d2f5be"><gtr:id>e84b7b240a215a94b2e6183626d2f5be</gtr:id><gtr:otherNames>Karlsen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2047-6302</gtr:issn><gtr:outcomeId>doi_53d06b06be217313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E120147E-1C03-4518-976A-11FCF67BD25E</gtr:id><gtr:title>Structural stability of E. coli transketolase to temperature and pH denaturation.</gtr:title><gtr:parentPublicationTitle>Journal of biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/772f5e34ae958d46961f56f45b12bb99"><gtr:id>772f5e34ae958d46961f56f45b12bb99</gtr:id><gtr:otherNames>Jahromi RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-1656</gtr:issn><gtr:outcomeId>doi_53cff8ff8acdf3fa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F642FBE-732C-4808-B5F5-241F856F52FA</gtr:id><gtr:title>Precipitation of filamentous bacteriophages for their selective recovery in primary purification.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60bc0af7688652a48e179ad1f197efda"><gtr:id>60bc0af7688652a48e179ad1f197efda</gtr:id><gtr:otherNames>Branston S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc25fc9b71</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FED38AA-E2BF-47BC-B844-3D8952FB6B40</gtr:id><gtr:title>Identification of Protein-Excipient Interaction Hotspots Using Computational Approaches.</gtr:title><gtr:parentPublicationTitle>International journal of molecular sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/013699000bad53a63032110a7518bd6f"><gtr:id>013699000bad53a63032110a7518bd6f</gtr:id><gtr:otherNames>Barata TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1422-0067</gtr:issn><gtr:outcomeId>58416c7e26d7b4.80948989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E4E4CA9-F01B-4E44-8161-9B47F1B51AC2</gtr:id><gtr:title>Optimising chromatography strategies of antibody purification processes by mixed integer fractional programming techniques</gtr:title><gtr:parentPublicationTitle>Computers &amp; Chemical Engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1aa8b1fe9f61c65a49629023b602564"><gtr:id>e1aa8b1fe9f61c65a49629023b602564</gtr:id><gtr:otherNames>Liu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54627b6d597138.82982742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6725F590-15ED-4434-B45F-2A69CDAA2205</gtr:id><gtr:title>Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0493491deea0d71dd646dd349ffd1896"><gtr:id>0493491deea0d71dd646dd349ffd1896</gtr:id><gtr:otherNames>Chakroun N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>56aa0fadc6bed4.00957745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B51632DA-BBD4-4736-A4AB-43D71C353D8E</gtr:id><gtr:title>Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dff8199fec6dbd0350e8f93dc486863d"><gtr:id>dff8199fec6dbd0350e8f93dc486863d</gtr:id><gtr:otherNames>Pollock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn><gtr:outcomeId>doi_53cfe9fe94fcdffc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C3FAAC4-F6D0-4A52-BD67-37F37EE4B85B</gtr:id><gtr:title>Growth and productivity impacts of periplasmic nuclease expression in an Escherichia coli Fab' fragment production strain.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/702609b07ea3d78960f1e334be7f3a9d"><gtr:id>702609b07ea3d78960f1e334be7f3a9d</gtr:id><gtr:otherNames>Nesbeth DN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc23e48a62</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>080CAEEB-85A2-4482-9A00-789F23E2C763</gtr:id><gtr:title>Patient and public preferences for health states associated with AMD.</gtr:title><gtr:parentPublicationTitle>Optometry and vision science : official publication of the American Academy of Optometry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca3f43a8dffc82ea255d6839281df3d4"><gtr:id>ca3f43a8dffc82ea255d6839281df3d4</gtr:id><gtr:otherNames>Butt T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1040-5488</gtr:issn><gtr:outcomeId>doi_53d0480486f0b763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6DA66BF-0584-444D-8801-CEF92B9DF552</gtr:id><gtr:title>Continuous Processing in Pharmaceutical Manufacturing</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca23dbb248e11fd19be8e609d46cbd02"><gtr:id>ca23dbb248e11fd19be8e609d46cbd02</gtr:id><gtr:otherNames>Farid S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5886a8b6b71db8.45419306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71A12682-4808-4A88-8628-46E1AFE29EAF</gtr:id><gtr:title>Noncovalent complexation of amphotericin-B with Poly(a-glutamic acid).</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/743f63d512ba4a6cc48138715fbbdc85"><gtr:id>743f63d512ba4a6cc48138715fbbdc85</gtr:id><gtr:otherNames>Mohamed-Ahmed AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>doi_53d01b01b2daaff5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54F2E9F8-2CE1-4A9C-9F10-E03E363C9E57</gtr:id><gtr:title>Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6da3e5250e12d62f83a12b0e9ba1bc76"><gtr:id>6da3e5250e12d62f83a12b0e9ba1bc76</gtr:id><gtr:otherNames>Barata T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>doi_53cfe6fe6bfe27e5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FA0171F-686A-4B33-8D2C-DA97A679FB4E</gtr:id><gtr:title>Process change evaluation framework for allogeneic cell therapies: impact on drug development and commercialization.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c640954e72ae94095e182bbfad5fdfc"><gtr:id>1c640954e72ae94095e182bbfad5fdfc</gtr:id><gtr:otherNames>Hassan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>5886a8b3319bb9.84906679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7788A4DC-9E8D-41B1-A1E1-6EEE874D01E7</gtr:id><gtr:title>Measuring current and future cost of skin cancer in England</gtr:title><gtr:parentPublicationTitle>Journal of Public Health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8112312354e7cebdaa15cadf26066bf"><gtr:id>b8112312354e7cebdaa15cadf26066bf</gtr:id><gtr:otherNames>L. Vallejo-Torres (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_3865063886136bcd18</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68B81711-7A5E-4E1D-BD39-C55201730CD9</gtr:id><gtr:title>Mathematical programming approaches for downstream processing optimisation of biopharmaceuticals</gtr:title><gtr:parentPublicationTitle>Chemical Engineering Research and Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1aa8b1fe9f61c65a49629023b602564"><gtr:id>e1aa8b1fe9f61c65a49629023b602564</gtr:id><gtr:otherNames>Liu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>02638762</gtr:issn><gtr:outcomeId>5886a8b81acbe0.92464299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C909DAA-9491-4826-967D-600B0869E4AA</gtr:id><gtr:title>Relationship between preparation of cells for therapy and cell quality using artificial neural network analysis.</gtr:title><gtr:parentPublicationTitle>Artificial intelligence in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ede33bcd9f6b66e276e1a933eed4ee00"><gtr:id>ede33bcd9f6b66e276e1a933eed4ee00</gtr:id><gtr:otherNames>Dhondalay GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0933-3657</gtr:issn><gtr:outcomeId>doi_55f978978127229b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC3D6BAA-9284-42E0-A6F9-A00F5E840803</gtr:id><gtr:title>Measuring current and future cost of skin cancer in England.</gtr:title><gtr:parentPublicationTitle>Journal of public health (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e23bf6872e4e1b4f62d290abd99df515"><gtr:id>e23bf6872e4e1b4f62d290abd99df515</gtr:id><gtr:otherNames>Vallejo-Torres L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1741-3842</gtr:issn><gtr:outcomeId>doi_53d0480481c6b6df</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB24D315-09EA-45E1-9ACE-5391887A0F44</gtr:id><gtr:title>Pathway-level disease data mining through hyper-box principles.</gtr:title><gtr:parentPublicationTitle>Mathematical biosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/567a6df44fe9ec1809d4232be794446a"><gtr:id>567a6df44fe9ec1809d4232be794446a</gtr:id><gtr:otherNames>Yang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0025-5564</gtr:issn><gtr:outcomeId>doi_55faa0aa09e2787b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C736EF53-5694-40A4-A0B2-872A6AE22001</gtr:id><gtr:title>Systematic review of drug administration costs and implications for biopharmaceutical manufacturing.</gtr:title><gtr:parentPublicationTitle>Applied health economics and health policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d83a7424ae4f886d3f13fc509327f848"><gtr:id>d83a7424ae4f886d3f13fc509327f848</gtr:id><gtr:otherNames>Tetteh E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1175-5652</gtr:issn><gtr:outcomeId>doi_53cfe0fe0a26c691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>548463DF-7A02-4822-92A4-5155352E8AD8</gtr:id><gtr:title>Integration of stochastic simulation with multivariate analysis: short-term facility fit prediction.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73c036a370c33f255b10a1d52aaefd3d"><gtr:id>73c036a370c33f255b10a1d52aaefd3d</gtr:id><gtr:otherNames>Stonier A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc2548544d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1664813B-95E9-467D-B973-C2B393D7F535</gtr:id><gtr:title>The Hybrid Experimental Simplex Algorithm for ?sweet spot? identification in early bioprocess development: Applications, Challenges, Recommendations.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d57a111e6c8312d6e9645c2effba9bd"><gtr:id>7d57a111e6c8312d6e9645c2effba9bd</gtr:id><gtr:otherNames>S Konstantinidis (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_89157063951404f308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80939D98-1193-4574-989F-47B2B70A5399</gtr:id><gtr:title>Advanced multivariate data analysis to determine the root cause of trisulfide bond formation in a novel antibody-peptide fusion.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/471ecf4a68a8e523c8b54f457a93b2e6"><gtr:id>471ecf4a68a8e523c8b54f457a93b2e6</gtr:id><gtr:otherNames>Goldrick S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>5a2fdf2b49ba24.79466423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE8F97C8-E5A0-411D-87E7-8DC7BC487333</gtr:id><gtr:title>Continuous protein purification using functionalized magnetic nanoparticles in aqueous micellar two-phase systems.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5770a170e3f02ad326f345dc79f87ff5"><gtr:id>5770a170e3f02ad326f345dc79f87ff5</gtr:id><gtr:otherNames>Fischer I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn><gtr:outcomeId>doi_53cfe9fe951e273c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34079115-520A-4328-948F-979016317787</gtr:id><gtr:title>Inducing protein aggregation by extensional flow.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b72cbd9ec69bb71687b05f49c32ad92f"><gtr:id>b72cbd9ec69bb71687b05f49c32ad92f</gtr:id><gtr:otherNames>Dobson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a352b7319d6f6.21526888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4D1028F-DA19-4680-A28E-A42720146151</gtr:id><gtr:title>Integrated Optimization of Upstream and Downstream Processing in Biopharmaceutical Manufacturing under Uncertainty: A Chance Constrained Programming Approach</gtr:title><gtr:parentPublicationTitle>Industrial &amp; Engineering Chemistry Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1aa8b1fe9f61c65a49629023b602564"><gtr:id>e1aa8b1fe9f61c65a49629023b602564</gtr:id><gtr:otherNames>Liu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56deeb67c0dd05.96446047</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AE433CF-9199-4338-9156-AA007DD9D318</gtr:id><gtr:title>Optimisation and Closed-loop Control of Crystal Shape Distribution in Seeded Cooling Crystallisation of L-Glutamic Acid</gtr:title><gtr:parentPublicationTitle>IFAC Proceedings Volumes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/614499d6dfd60e0aac13fcc6156c92cd"><gtr:id>614499d6dfd60e0aac13fcc6156c92cd</gtr:id><gtr:otherNames>Yang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53d086086044fd40</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EE5BC22-CB26-45BD-8D55-3A2D11DDF842</gtr:id><gtr:title>The Hybrid Experimental Simplex Algorithm (HESA) for early bioprocess development</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acb4b5bb4393dd197df60c9d1c8004b3"><gtr:id>acb4b5bb4393dd197df60c9d1c8004b3</gtr:id><gtr:otherNames>Nigel Titchener-Hooker (Co-author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_481691316413f464e8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0E177DD-83FF-4A89-84E9-D3F809CF542B</gtr:id><gtr:title>Tools for the integration of fermentation and DSP</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1632a18e0daed7844a229dc28c5ac7a9"><gtr:id>1632a18e0daed7844a229dc28c5ac7a9</gtr:id><gtr:otherNames>Nigel Titchener-Hooker (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_542660163113f46394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74A64DAE-F3AE-453A-85C3-59DC87F0F193</gtr:id><gtr:title>Methods for rapid process characterisation in the successful translation of process technologies</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1632a18e0daed7844a229dc28c5ac7a9"><gtr:id>1632a18e0daed7844a229dc28c5ac7a9</gtr:id><gtr:otherNames>Nigel Titchener-Hooker (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>m_821934350213f46448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDC9F6E1-75D7-40C6-BE1B-FE66D8AAE11A</gtr:id><gtr:title>Representative mammalian cell culture test materials for assessment of primary recovery technologies: a rapid method with industrial applicability.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec2c3140ec97ab4abe01f43b158ae776"><gtr:id>ec2c3140ec97ab4abe01f43b158ae776</gtr:id><gtr:otherNames>Popova D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>56d5a2eaa16ce6.83259901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37DB0A10-6A39-412E-A465-A92724E1953C</gtr:id><gtr:title>Optimization of multi-product antibody facility designs: a genetic algorithm approach</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf5d9ef09b13dbe70a7107e67025a304"><gtr:id>bf5d9ef09b13dbe70a7107e67025a304</gtr:id><gtr:otherNames>Sofia Simaria (Speaker)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_96980026451406fa18</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98B9AC07-5F48-43F4-8158-D3C4BFEE289E</gtr:id><gtr:title>A multiobjective evolutionary optimization framework for protein purification process design</gtr:title><gtr:parentPublicationTitle>Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40327c7d26c2bddafaf8596200c75e1d"><gtr:id>40327c7d26c2bddafaf8596200c75e1d</gtr:id><gtr:otherNames>Allmendinger R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>16113349 03029743</gtr:issn><gtr:outcomeId>5886a8b4e48e96.44305940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E638753F-D4EE-4882-951A-7D7CA30A48F1</gtr:id><gtr:title>Function after spinal treatment, exercise and rehabilitation (FASTER): improving the functional outcome of spinal surgery.</gtr:title><gtr:parentPublicationTitle>BMC musculoskeletal disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3952192971eaad823df62761afb89f6"><gtr:id>c3952192971eaad823df62761afb89f6</gtr:id><gtr:otherNames>McGregor AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2474</gtr:issn><gtr:outcomeId>doi_53d07b07b90635dd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE10C440-0B7E-4C42-BB50-52DC48AF7B45</gtr:id><gtr:title>From sequence to 3D structure of hyperbranched molecules: application to surface modified PAMAM dendrimers.</gtr:title><gtr:parentPublicationTitle>Journal of molecular modeling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/013699000bad53a63032110a7518bd6f"><gtr:id>013699000bad53a63032110a7518bd6f</gtr:id><gtr:otherNames>Barata TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0948-5023</gtr:issn><gtr:outcomeId>doi_53cfd7fd7cf31faa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2279DA2-4065-4103-A990-0AE2296E19D4</gtr:id><gtr:title>Use of focused acoustics for cell disruption to provide ultra scale-down insights of microbial homogenization and its bioprocess impact--recovery of antibody fragments from rec E. coli.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f6924f8765fc02490873fd4b290945"><gtr:id>99f6924f8765fc02490873fd4b290945</gtr:id><gtr:otherNames>Li Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc2457abd8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0F5A6C3-B9A4-4448-8479-0FF9C9F1ED30</gtr:id><gtr:title>Dual salt precipitation for the recovery of a recombinant protein from Escherichia coli.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6135f86398cc0e44282326d67ad2d604"><gtr:id>6135f86398cc0e44282326d67ad2d604</gtr:id><gtr:otherNames>Balasundaram B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc25d364a9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C45E5C46-FA38-4C6A-BF28-C82136E5BD99</gtr:id><gtr:title>A scale-down mimic for mapping the process performance of centrifugation, depth and sterile filtration.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbcf00607ff4cc2cce757e11e9003d60"><gtr:id>cbcf00607ff4cc2cce757e11e9003d60</gtr:id><gtr:otherNames>Joseph A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>5886a8b77ff0f0.96329049</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F86901B-6CC2-4D18-B4F6-59E2F8EF62AE</gtr:id><gtr:title>Biopharmaceutical Production Technology - SUBRAMANIAN:BIOPH TECH 2V O-BK</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca23dbb248e11fd19be8e609d46cbd02"><gtr:id>ca23dbb248e11fd19be8e609d46cbd02</gtr:id><gtr:otherNames>Farid S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5886a8b7193e79.28905565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD13B643-E3A2-45C0-81F1-1EFF7910B95F</gtr:id><gtr:title>Integrated economic and experimental framework for screening of primary recovery technologies for high cell density CHO cultures.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec2c3140ec97ab4abe01f43b158ae776"><gtr:id>ec2c3140ec97ab4abe01f43b158ae776</gtr:id><gtr:otherNames>Popova D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>5886a8b3de87c7.49871945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F58B54BF-DCC0-4039-BB0A-083C42797497</gtr:id><gtr:title>Comparative binding of disulfide-bridged PEG-Fabs.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b037483788333cb668ff56beb88c002"><gtr:id>6b037483788333cb668ff56beb88c002</gtr:id><gtr:otherNames>Khalili H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>doi_53d014014503913c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CBE43BA-A46E-4E38-8431-1ECD60FE72AD</gtr:id><gtr:title>A generic hierarchical screening method for the analysis of microscale refolds using an automated robotic platform.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55cea7316e13e76ea40a42c5ecfa45fd"><gtr:id>55cea7316e13e76ea40a42c5ecfa45fd</gtr:id><gtr:otherNames>Ordidge GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc24f360ef</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65768F4E-EB42-4919-8393-BA6578EB9056</gtr:id><gtr:title>Cost-Effectiveness and robustness evaluation for biomanufacturing</gtr:title><gtr:parentPublicationTitle>BioProcess International</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c71e62f209c299d02c84472b2e8f2f65"><gtr:id>c71e62f209c299d02c84472b2e8f2f65</gtr:id><gtr:otherNames>Farid S.S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>15426319</gtr:issn><gtr:outcomeId>5886a8b5483169.63123965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06E43A9A-CB42-4A5D-9839-3A2F6CD2662C</gtr:id><gtr:title>Thermodynamic parameters for salt-induced reversible protein precipitation from automated microscale experiments.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f2d6aca0205be72f023a550fe998029"><gtr:id>4f2d6aca0205be72f023a550fe998029</gtr:id><gtr:otherNames>Ahmad SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc23661a73</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE4C57C2-3A12-46F9-A4E6-6D40664E04E9</gtr:id><gtr:title>Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor.</gtr:title><gtr:parentPublicationTitle>Biotechnology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6614c68f7c331c21bb4ea69bd30a00d1"><gtr:id>6614c68f7c331c21bb4ea69bd30a00d1</gtr:id><gtr:otherNames>Grant Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0141-5492</gtr:issn><gtr:outcomeId>doi_53cfd9fd99ce0a55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2503AFA2-9D8F-4971-BD19-A3D3D85FA802</gtr:id><gtr:title>Income-related inequity in healthcare utilisation among individuals with cardiovascular disease in England-accounting for vertical inequity.</gtr:title><gtr:parentPublicationTitle>Health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e23bf6872e4e1b4f62d290abd99df515"><gtr:id>e23bf6872e4e1b4f62d290abd99df515</gtr:id><gtr:otherNames>Vallejo-Torres L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1057-9230</gtr:issn><gtr:outcomeId>doi_53cfc5fc5384b5c5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89ADA0BF-82EB-4924-8B52-320D0D815B60</gtr:id><gtr:title>How implementation of Quality by Design and advances in Biochemical Engineering are enabling efficient bioprocess development and manufacture</gtr:title><gtr:parentPublicationTitle>Journal of Chemical Technology &amp; Biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a29fbac184681cef8193fe80a5dade52"><gtr:id>a29fbac184681cef8193fe80a5dade52</gtr:id><gtr:otherNames>Chhatre S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>02682575</gtr:issn><gtr:outcomeId>5886a8b7e5be20.61212124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A995B365-7FF2-48FF-856D-D3CC7B064B91</gtr:id><gtr:title>An MILP formulation for the synthesis of protein purification processes</gtr:title><gtr:parentPublicationTitle>Chemical Engineering Research and Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9813f110add19d9c418fa19a30a48a37"><gtr:id>9813f110add19d9c418fa19a30a48a37</gtr:id><gtr:otherNames>Polykarpou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53cfe9fe9305118b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5B3DA22-5D5C-4190-A5B6-0F80051703C9</gtr:id><gtr:title>A mixed-integer nonlinear programming model for antibody purification processes</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd93141b34c29090c20806a54d1bcce"><gtr:id>acd93141b34c29090c20806a54d1bcce</gtr:id><gtr:otherNames>Song Song Liu (Speaker)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_52641904561406fc20</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9502138E-AE39-458E-8CD7-6AF0674EB1D8</gtr:id><gtr:title>Chromatography modelling to describe protein adsorption at bead level.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d9730abefad3e23e8f5a96c64934a3d"><gtr:id>1d9730abefad3e23e8f5a96c64934a3d</gtr:id><gtr:otherNames>Gerontas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn><gtr:outcomeId>doi_53cfe9fe95065493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75DA62BB-F7D9-4B41-B4E6-E4C0922011D5</gtr:id><gtr:title>Site-specific PEGylation at histidine tags.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d75da10a861e2b64c82c8c8da7ff64b5"><gtr:id>d75da10a861e2b64c82c8c8da7ff64b5</gtr:id><gtr:otherNames>Cong Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>doi_53d0140144fa927e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A219ACF2-9474-4360-B7EC-4DD126556163</gtr:id><gtr:title>Women's and Health Professionals' Preferences for Prenatal Tests for Down Syndrome</gtr:title><gtr:parentPublicationTitle>Obstetrical &amp; Gynecological Survey</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f621ebdfe79c292f3dfa8e47270f642"><gtr:id>8f621ebdfe79c292f3dfa8e47270f642</gtr:id><gtr:otherNames>Hill M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53d0480486e6a1b9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>028AFBBF-A5C4-424D-AFBC-E906486883D1</gtr:id><gtr:title>Optimal synthesis of chromatographic trains for downstream protein processing.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/446846fe6e6dde0f2f54d7b16862d263"><gtr:id>446846fe6e6dde0f2f54d7b16862d263</gtr:id><gtr:otherNames>Polykarpou EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc25dbb611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>238B1DF5-E9F2-4198-BF52-62EFDEC9E120</gtr:id><gtr:title>Fundamentals and applications of immobilized microfluidic enzymatic reactors</gtr:title><gtr:parentPublicationTitle>Journal of Chemical Technology &amp; Biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50da6c16ab77d39f470eb7c63ef1257f"><gtr:id>50da6c16ab77d39f470eb7c63ef1257f</gtr:id><gtr:otherNames>Matosevic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53cfc6fc603d5215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E321BA59-983C-431F-B73E-3774A5311FE8</gtr:id><gtr:title>Preparation and characterisation of amphotericin B-copolymer complex for the treatment of leishmaniasis</gtr:title><gtr:parentPublicationTitle>Polym. Chem.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c287b3165d53810926206393ec06356"><gtr:id>2c287b3165d53810926206393ec06356</gtr:id><gtr:otherNames>Mohamed-Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53d02f02fc707af9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6DFB6E4-EB1A-4A84-B2F2-8C922819320A</gtr:id><gtr:title>A multi-level meta-heuristic algorithm for the optimisation of antibody purification processes</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d43029930498a4587bedf8548ee76bb2"><gtr:id>d43029930498a4587bedf8548ee76bb2</gtr:id><gtr:otherNames>Simaria A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>54627b6ed58d98.32389721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEA2AC6E-E41D-4414-85FE-8D7DF2B64D60</gtr:id><gtr:title>Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7afee3ad4239ec27eee53678a31df16"><gtr:id>c7afee3ad4239ec27eee53678a31df16</gtr:id><gtr:otherNames>Looby M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc25eb7415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50059882-F337-480D-93FA-64779325CBB6</gtr:id><gtr:title>Fab-PEG-Fab as a potential antibody mimetic.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b037483788333cb668ff56beb88c002"><gtr:id>6b037483788333cb668ff56beb88c002</gtr:id><gtr:otherNames>Khalili H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>doi_53d0140145159437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37F6030B-AC0A-4717-8CF7-48BCB6D26C8C</gtr:id><gtr:title>Continuous bioprocessing: the real thing this time? 10(th) Annual bioProcessUK Conference, December 3-4, 2013, London, UK.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c10ebc24ac3e062a6b2c45170b268e1d"><gtr:id>c10ebc24ac3e062a6b2c45170b268e1d</gtr:id><gtr:otherNames>Farid SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn><gtr:outcomeId>5886a8b60ed026.85137714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5544858-4165-458D-9D1A-A1850C78E3AC</gtr:id><gtr:title>Ultra scale-down of protein refold screening in microwells: challenges, solutions and application.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86fdbd4051a56e833bbec967c33f183b"><gtr:id>86fdbd4051a56e833bbec967c33f183b</gtr:id><gtr:otherNames>Mannall GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc22e89edf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A9CDADE-245A-420F-9F3F-A6FE2159C5FF</gtr:id><gtr:title>Investigating the use of column inserts to achieve better chromatographic bed support.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe98462ae987560f10c37021698c0e81"><gtr:id>fe98462ae987560f10c37021698c0e81</gtr:id><gtr:otherNames>Lan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc2533819c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1049B60F-BFE0-432C-BAA7-7C37AC616675</gtr:id><gtr:title>Hybrid experimental simplex algorithm, a novel optimization method for high throughput experimentation: Case studies in ion exchange chromatography</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f16fc536bfab1f33902297d66caaed3"><gtr:id>3f16fc536bfab1f33902297d66caaed3</gtr:id><gtr:otherNames>S Konstantinidis  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_66205409671404f25e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF792919-E6B8-4E5C-8C9C-9720D1C5F361</gtr:id><gtr:title>Research themes in Advanced Manufacturing in the UK ? Bioprocessing</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1632a18e0daed7844a229dc28c5ac7a9"><gtr:id>1632a18e0daed7844a229dc28c5ac7a9</gtr:id><gtr:otherNames>Nigel Titchener-Hooker (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_963788820113f462e0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC10639F-FBC9-44FF-B7E4-B0D0D8F45B92</gtr:id><gtr:title>Decisional tool to assess current and future process robustness in an antibody purification facility.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73c036a370c33f255b10a1d52aaefd3d"><gtr:id>73c036a370c33f255b10a1d52aaefd3d</gtr:id><gtr:otherNames>Stonier A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc2512222b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E23E9909-0A78-4230-97D6-F4DB740A7C89</gtr:id><gtr:title>Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c640954e72ae94095e182bbfad5fdfc"><gtr:id>1c640954e72ae94095e182bbfad5fdfc</gtr:id><gtr:otherNames>Hassan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>5886a8b525b183.60931761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>215A0D70-E999-49B8-9CFE-9A2B2F5CC2B1</gtr:id><gtr:title>Chromatography modelling at bead level for bioprocess design and understanding</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c369b745c483f946d7b2fa67ba7f546d"><gtr:id>c369b745c483f946d7b2fa67ba7f546d</gtr:id><gtr:otherNames>Daniel  Bracewell (Co-author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_503658877613dd0d8e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>469E6F21-0E92-4034-AAF7-A9DC246202E6</gtr:id><gtr:title>New developments in the pharmacological modulation of wound healing after glaucoma filtration surgery.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78f4e90605dcc535862ac16b713265"><gtr:id>8e78f4e90605dcc535862ac16b713265</gtr:id><gtr:otherNames>Lockwood A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>doi_53cfeafeaca27ee7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3995933-6769-4DBF-8580-C5166E057BB9</gtr:id><gtr:title>Rapid prediction of facility fit and debottlenecking of antibody purification facilities</gtr:title><gtr:parentPublicationTitle>Food, Pharmaceutical and Bioengineering Division 2014 - Core Programming Area at the 2014 AIChE Annual Meeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189e061b8ce0af7e94f7a4f7ed0c96d7"><gtr:id>189e061b8ce0af7e94f7a4f7ed0c96d7</gtr:id><gtr:otherNames>Yang Y.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5886a8b842f245.10537663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A26CC831-E309-4A0B-9314-D62B46F7D4E0</gtr:id><gtr:title>Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dff8199fec6dbd0350e8f93dc486863d"><gtr:id>dff8199fec6dbd0350e8f93dc486863d</gtr:id><gtr:otherNames>Pollock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc2468e40d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E2CD415-D2EE-45CA-813B-D5622DABF5E4</gtr:id><gtr:title>Evaluation of a structural mechanics model to predict the effect of inserts in the bed support of chromatographic columns</gtr:title><gtr:parentPublicationTitle>Chemical Engineering Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d9730abefad3e23e8f5a96c64934a3d"><gtr:id>1d9730abefad3e23e8f5a96c64934a3d</gtr:id><gtr:otherNames>Gerontas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>doi_55faa0aa09cdc137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EB89CC6-BE9F-4221-9C77-DF3640F13EE5</gtr:id><gtr:title>Strategic Assay Selection for analytics in high-throughput process development: case studies for downstream processing of monoclonal antibodies.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fbe47e0e9d172812888efa2471b1486"><gtr:id>4fbe47e0e9d172812888efa2471b1486</gtr:id><gtr:otherNames>Konstantinidis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>doi_53cfc2fc226b024f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86693594-BDFA-4B86-8A80-8BCBCF8A45D2</gtr:id><gtr:title>Multiobjective evolutionary optimization in antibody purification process design</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15f30a4c37a23d9e97b4e449981e7764"><gtr:id>15f30a4c37a23d9e97b4e449981e7764</gtr:id><gtr:otherNames>Allmendinger R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_55f978978130a246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5903CF7D-11F9-438B-9E9D-5612543A3835</gtr:id><gtr:title>A decision-support tool for the optimal design of multi-product biopharmaceutical facilities</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf5d9ef09b13dbe70a7107e67025a304"><gtr:id>bf5d9ef09b13dbe70a7107e67025a304</gtr:id><gtr:otherNames>Sofia Simaria (Speaker)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_79703950071406f964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28BEAB11-D24E-4899-BE42-DCDB9406A511</gtr:id><gtr:title>Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df5dab2d58f5d48407448135c9c4da20"><gtr:id>df5dab2d58f5d48407448135c9c4da20</gtr:id><gtr:otherNames>Jenkins M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1873295X</gtr:issn><gtr:outcomeId>5886a8b5d6c983.72460179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C8919E-502C-47AE-B04A-FA18BE8D6586</gtr:id><gtr:title>Immobilised enzyme microreactor for screening of multi-step bioconversions: characterisation of a de novo transketolase-?-transaminase pathway to synthesise chiral amino alcohols.</gtr:title><gtr:parentPublicationTitle>Journal of biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50da6c16ab77d39f470eb7c63ef1257f"><gtr:id>50da6c16ab77d39f470eb7c63ef1257f</gtr:id><gtr:otherNames>Matosevic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-1656</gtr:issn><gtr:outcomeId>doi_53cff8ff8b08b2e6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82F10934-79A9-46F8-B1DE-5212D1EFA55A</gtr:id><gtr:title>The simplex algorithm for the rapid identification of operating conditions during early bioprocess development: case studies in FAb' precipitation and multimodal chromatography.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a29fbac184681cef8193fe80a5dade52"><gtr:id>a29fbac184681cef8193fe80a5dade52</gtr:id><gtr:otherNames>Chhatre S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc23c71f9f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD694ED1-43F3-4AE5-9036-F88BC3885253</gtr:id><gtr:title>Electrospun formulations of acyclovir, ciprofloxacin and cyanocobalamin for ocular drug delivery.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e2a4293bbd23ee88d4581804a11c335"><gtr:id>7e2a4293bbd23ee88d4581804a11c335</gtr:id><gtr:otherNames>Baskakova A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>585d4ed18b29e1.87638083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7D7E349-E3FD-4F11-A7B5-7DEA3448443B</gtr:id><gtr:title>Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7f30de843078e4990cb8cb50a0ef4d0"><gtr:id>d7f30de843078e4990cb8cb50a0ef4d0</gtr:id><gtr:otherNames>Simaria AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc24870b60</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA0ED88E-F490-4A22-B634-92F9D332B8A1</gtr:id><gtr:title>Scale-down prediction of industrial scale pleated membrane cartridge performance.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e7f51fa90ded7babd8919700bacb90a"><gtr:id>4e7f51fa90ded7babd8919700bacb90a</gtr:id><gtr:otherNames>Brown AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc2377bf2c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CA50682-BC5B-4469-AFF7-0FEFFAF02997</gtr:id><gtr:title>Abandoning Geometric Rules ? the Evolution of Ultra Scale-Down</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1632a18e0daed7844a229dc28c5ac7a9"><gtr:id>1632a18e0daed7844a229dc28c5ac7a9</gtr:id><gtr:otherNames>Nigel Titchener-Hooker (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>m_920946688713f4615a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42B6D42E-C0D6-40F5-97C2-65DC1D94138F</gtr:id><gtr:title>On-Line Control of Glucose Concentration in High-Yielding Mammalian Cell Cultures Enabled Through Oxygen Transfer Rate Measurements.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/471ecf4a68a8e523c8b54f457a93b2e6"><gtr:id>471ecf4a68a8e523c8b54f457a93b2e6</gtr:id><gtr:otherNames>Goldrick S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>5a66fc14cd18f0.53809909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>711A3F40-218A-4FB5-9A20-3E01C1892137</gtr:id><gtr:title>Automated methods for accurate determination of the critical velocity of packed bed chromatography.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88ecd6b1bf0f8c429761830392d9bd57"><gtr:id>88ecd6b1bf0f8c429761830392d9bd57</gtr:id><gtr:otherNames>Chang YC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc2505700e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>617D5C89-EDE3-4F11-8AE2-AA0DBCBF9940</gtr:id><gtr:title>The cost analysis of cemented versus cementless total hip replacement operations on the NHS.</gtr:title><gtr:parentPublicationTitle>The bone &amp; joint journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad84283410bcf0a173bd58e04c930cf1"><gtr:id>ad84283410bcf0a173bd58e04c930cf1</gtr:id><gtr:otherNames>Kallala R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2049-4394</gtr:issn><gtr:outcomeId>doi_53d07e07e05c40e1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6F71070-69A5-4A65-A812-0649BF9E1A07</gtr:id><gtr:title>Multiobjective optimisation of production, distribution and capacity planning of global supply chains in the process industry</gtr:title><gtr:parentPublicationTitle>Omega</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1aa8b1fe9f61c65a49629023b602564"><gtr:id>e1aa8b1fe9f61c65a49629023b602564</gtr:id><gtr:otherNames>Liu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53d0030037f65ecd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF837510-143D-4443-BA10-86738667B114</gtr:id><gtr:title>Optically induced thermal gradients for protein characterization in nanolitre-scale samples in microfluidic devices.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/636acc287110afb927fc28c4e6200d67"><gtr:id>636acc287110afb927fc28c4e6200d67</gtr:id><gtr:otherNames>Sagar DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>541abd33425693.71630456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8B03033-40B9-4B5B-8304-23C5AB1B1CEB</gtr:id><gtr:title>T-Values and Unfolded Fraction Can Predict Aggregation Rates for Granulocyte Colony Stimulating Factor Variant Formulations but Not under Predominantly Native Conditions.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b8b501485f620456c0b15ece1cb914d"><gtr:id>2b8b501485f620456c0b15ece1cb914d</gtr:id><gtr:otherNames>Robinson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>5a3529a281bbf1.06674105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD773ADE-2E95-4959-A47B-AB343C45B28D</gtr:id><gtr:title>Function after spinal treatment, exercise, and rehabilitation: cost-effectiveness analysis based on a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Spine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d0d85071e75916a8f09a9815ed0c74e"><gtr:id>7d0d85071e75916a8f09a9815ed0c74e</gtr:id><gtr:otherNames>Morris S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0362-2436</gtr:issn><gtr:outcomeId>doi_53d048048656fa40</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DDBE8DD-5BD5-4261-88F9-CE2F267D9B3C</gtr:id><gtr:title>Mathematical programming formulations for non-smooth and non-convex electricity dispatch problems</gtr:title><gtr:parentPublicationTitle>Electric Power Systems Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/567a6df44fe9ec1809d4232be794446a"><gtr:id>567a6df44fe9ec1809d4232be794446a</gtr:id><gtr:otherNames>Yang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53cff3ff31bafde7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C296E48-FEE9-4F3B-B5D0-F2BEE04A7C6F</gtr:id><gtr:title>Data mining for rapid prediction of facility fit and debottlenecking of biomanufacturing facilities.</gtr:title><gtr:parentPublicationTitle>Journal of biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/614499d6dfd60e0aac13fcc6156c92cd"><gtr:id>614499d6dfd60e0aac13fcc6156c92cd</gtr:id><gtr:otherNames>Yang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-1656</gtr:issn><gtr:outcomeId>56afe1e3ee89e8.61117994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A0DCD56-48FC-4C82-A52A-1542C2B2AE3F</gtr:id><gtr:title>A new lot sizing and scheduling heuristic for multi-site biopharmaceutical production</gtr:title><gtr:parentPublicationTitle>Journal of Heuristics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2974edeb8bfb71774911df4337e32089"><gtr:id>2974edeb8bfb71774911df4337e32089</gtr:id><gtr:otherNames>Oyebolu F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fe079f2bea6.87720547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>781410C1-AF1A-4E5C-B677-D60556E43171</gtr:id><gtr:title>Characterization and stability of ternary solid dispersions with PVP and PHPMA.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75b3d19746153db84c7795f2090b77cd"><gtr:id>75b3d19746153db84c7795f2090b77cd</gtr:id><gtr:otherNames>Al-Obaidi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>doi_53cff7ff724f2839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D11EB3C6-D2FD-4E37-ACF0-E09353CF4DDD</gtr:id><gtr:title>Target fishing and docking studies of the novel derivatives of aryl-aminopyridines with potential anticancer activity.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c19f6f28bbad78296f8d6d48deb22b"><gtr:id>c4c19f6f28bbad78296f8d6d48deb22b</gtr:id><gtr:otherNames>Eric S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>doi_53cfe6fe6fd80a80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AB5D0DF-53D5-4BA2-A7B4-12921C0EB6B3</gtr:id><gtr:title>Study of the conditions for multi-modal chromatographic capture of Fab' from dual-salt precipitated
 
 homogenate</gtr:title><gtr:parentPublicationTitle>Journal of Chemical Technology &amp; Biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6135f86398cc0e44282326d67ad2d604"><gtr:id>6135f86398cc0e44282326d67ad2d604</gtr:id><gtr:otherNames>Balasundaram B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_53cfc6fc6079b2c3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1FC42FA-1B55-4FB8-B1B1-64CE59633869</gtr:id><gtr:title>Designing cost-effective biopharmaceutical facilities using mixed-integer optimization.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1aa8b1fe9f61c65a49629023b602564"><gtr:id>e1aa8b1fe9f61c65a49629023b602564</gtr:id><gtr:otherNames>Liu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc2558ca3b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7968404-0356-4F77-B98B-DE35744D88BE</gtr:id><gtr:title>Innovation in biopharmaceutical manufacture</gtr:title><gtr:parentPublicationTitle>BioProcess International</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f493e9e4f5c0cab077f160281d5b3ac4"><gtr:id>f493e9e4f5c0cab077f160281d5b3ac4</gtr:id><gtr:otherNames>Davidson A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>15426319</gtr:issn><gtr:outcomeId>54627ba7708191.53057611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE5E778D-5569-4E28-8A06-A1E4619DE29C</gtr:id><gtr:title>Characterization and feasibility of a miniaturized stirred tank bioreactor to perform E. coli high cell density fed-batch fermentations.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fffc67a4c7eec4e83a1fa42feaa78ef"><gtr:id>2fffc67a4c7eec4e83a1fa42feaa78ef</gtr:id><gtr:otherNames>Ali S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn><gtr:outcomeId>doi_53cfc2fc261c4d57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4222AD97-7968-432B-8A08-CAA154397B43</gtr:id><gtr:title>Identifying analytics for high throughput bioprocess development studies.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fbe47e0e9d172812888efa2471b1486"><gtr:id>4fbe47e0e9d172812888efa2471b1486</gtr:id><gtr:otherNames>Konstantinidis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>doi_53cfc2fc2472f834</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/I033270/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>85</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>85</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>DC402B6E-3B84-4EAB-AED8-9CB51552A1CE</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Macro-molecular delivery</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>